Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.001250%
Acne23.02.01.001---
Acute hepatic failure09.01.03.0010.001250%-
Acute myocardial infarction02.02.02.001; 24.04.04.001---
Ageusia07.14.03.003; 17.02.07.001---
Aggression19.05.01.001---
Alanine aminotransferase increased13.03.04.005--
Alcohol abuse19.07.06.001---
Alcohol intolerance14.02.01.001--
Alcoholism19.07.06.006---
Alopecia23.02.02.0010.004374%
Anaemia01.03.02.0010.001250%
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anorectal disorder07.03.01.001---
Anxiety19.06.02.002--
Arthralgia15.01.02.0010.005249%
Arthritis15.01.01.001--
Arthropathy15.01.01.0030.001250%-
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001---
Atrophic vulvovaginitis21.02.01.003---
Back pain15.03.04.005--
Balanoposthitis21.09.03.001---
Basal cell carcinoma16.03.02.001; 23.08.02.0010.001875%-
Basophil count increased13.01.06.002---
Bilirubin conjugated increased13.03.04.014---
Bleeding time prolonged13.01.02.002---
Blepharitis06.04.04.001; 23.03.04.012---
Blindness06.02.10.003; 17.17.01.003---
Blister12.01.06.002; 23.03.01.0010.001250%-
The 1th Page    1 2 3 4 5    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene